Treating adolescent ADHD without the cardiovascular risks and abuse potential of traditional stimulants has been a long-standing clinical challenge. A new phase III-level randomized controlled trial may offer a meaningful step forward, demonstrating that a novel triple-reuptake inhibitor can produce statistically significant symptom reduction within just one week of non-titrated dosing — a clinically relevant speed of onset for this age group.
The double-blind, placebo-controlled trial enrolled 459 adolescents aged 13–17 with a primary ADHD diagnosis, randomizing them to once-daily centanafadine at 164.4 mg, 328.8 mg, or placebo for six weeks. The higher dose achieved its primary endpoint: a significantly greater reduction in ADHD Rating Scale version 5 (ADHD-RS-5) total raw scores compared to placebo (−18.50 versus −14.15; p = .0006). Critically, this separation emerged at week one and was sustained across the study duration. The lower dose failed to meet the primary endpoint. Adverse events occurred in roughly half of participants on the higher dose — notably decreased appetite, nausea, headache, and rash — compared to about 24% on placebo, though most were mild to moderate in severity.
Centanafadine's mechanism — simultaneous inhibition of norepinephrine, dopamine, and serotonin reuptake — distinguishes it from both amphetamine-class stimulants and atomoxetine, the current non-stimulant standard. The triple-reuptake profile theoretically addresses inattentive, hyperactive, and mood-related dimensions simultaneously, which is pharmacologically intriguing but not yet validated against head-to-head comparisons with existing agents. The 4.35-point symptom score advantage over placebo is modest and must be interpreted in the context of what constitutes a clinically meaningful difference for individual patients. The six-week observation window is short, and long-term safety data — including effects on growth, sleep architecture, and cardiovascular parameters — remain essential before this compound could reshape adolescent ADHD prescribing. Nonetheless, as a registered RCT in a well-defined adolescent cohort, this represents a genuinely meaningful data point for non-stimulant ADHD pharmacotherapy.